Drugs & Therapy Perspectives

, Volume 28, Issue 12, pp 20–23 | Cite as

Manage drug-induced parkinsonism through early recognition of the condition and discontinuation of the causative agent

Drug Reactions and Interactions

Parkinsonism can be induced by many drugs, particularly dopamine receptor antagonists. Key strategies for managing drug-induced parkinsonism include prompt diagnosis and discontinuation or replacement of the offending drug. If symptoms persist, pharmacotherapy and electroconvulsive therapy are options.

Prevalence is increasing

Drug-induced parkinsonism is a reversible, pharmacotherapy-induced, rigid-akinetic syndrome that develops as a result of diminished stimulation of dopamine D2 receptors in the striatum.[1] Although estimations of the prevalence and incidence of the condition vary greatly, its prevalence appears to be growing as populations age and use of polypharmacy increases. Drug-induced parkinsonism is now considered to be the most widespread secondary parkinsonism in Western countries, yet is still under-recognized and could become a considerable future health concern. This article summarizes a recent review on the prevention and management of drug-induced parkinsonism by...


  1. 1.
    López-Sendón JL, Mena MA, de Yébenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012; 29 (2): 105–18PubMedCrossRefGoogle Scholar
  2. 2.
    Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51 (6): 850–4PubMedCrossRefGoogle Scholar
  3. 3.
    Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 1990; 2 (1): 64–6PubMedGoogle Scholar
  4. 4.
    Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004; 2004 (23): 26CrossRefGoogle Scholar
  5. 5.
    Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993; 70 (3–4): 193–7PubMedCrossRefGoogle Scholar
  6. 6.
    Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2 (8411): 1082–3PubMedCrossRefGoogle Scholar
  7. 7.
    Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Mov Disord 2011; 26 (6): 1083–95PubMedCrossRefGoogle Scholar
  8. 8.
    Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984; 45 (8): 331–6PubMedGoogle Scholar
  9. 9.
    Srinivasan TN, Thara R, Padmavathi R, et al. Relationship of extrapyramidal symptoms to age at onset and drug treatment in middle-aged and elderly schizophrenic patients. Schizophr Res 2001; 47 (1): 69–75PubMedCrossRefGoogle Scholar
  10. 10.
    Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22 (3): 313–8PubMedCrossRefGoogle Scholar
  11. 11.
    Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005; 20 (8): 958–63PubMedCrossRefGoogle Scholar
  12. 12.
    Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 1999; 14 (3): 484–7PubMedCrossRefGoogle Scholar
  13. 13.
    Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson’s disease. Postgrad Med J 2005; 81 (960): 644–6PubMedCrossRefGoogle Scholar
  14. 14.
    Nelli AC, Yarden PE, Guazzelli M, et al. Parkinsonism following neuroleptic withdrawal. Arch Gen Psychiatry 1989; 46 (4): 383–4PubMedCrossRefGoogle Scholar
  15. 15.
    Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmacovigilance [in French]. Rev Neurol (Paris) 1994; 150 (11): 757–62Google Scholar
  16. 16.
    Rajput AH, Rozdilsky B, Hornykiewicz O, et al. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982; 39 (10): 644–6PubMedCrossRefGoogle Scholar
  17. 17.
    Fahn WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976; 133 (8): 940–3Google Scholar
  18. 18.
    Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009; 256 (6): 910–5PubMedCrossRefGoogle Scholar
  19. 19.
    Baez MA, Avery J. Improvement in drug-induced parkinsonism with electroconvulsive therapy. Am J Geriatr Pharmacother 2011; 9 (3): 190–3PubMedCrossRefGoogle Scholar
  20. 20.
    Hanin B, Lerner Y, Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia. Convuls Ther 1995; 11 (4): 271–4PubMedGoogle Scholar
  21. 21.
    Goswami U, Dutta S, Kuruvilla K, et al. Electroconvulsive therapy in neuroleptic-induced parkinsonism. Biol Psychiatry 1989; 26 (3): 234–8PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Personalised recommendations